Geode Capital Management LLC Has $9.20 Million Stock Holdings in uniQure (NASDAQ:QURE)

Geode Capital Management LLC lifted its position in uniQure (NASDAQ:QURE) by 2.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 520,553 shares of the biotechnology company’s stock after buying an additional 11,951 shares during the quarter. Geode Capital Management LLC owned about 1.07% of uniQure worth $9,198,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Franklin Resources Inc. acquired a new position in uniQure during the 3rd quarter worth $7,360,000. FNY Investment Advisers LLC acquired a new position in shares of uniQure during the 4th quarter worth about $88,000. Sanders Morris Harris LLC boosted its stake in uniQure by 50.0% during the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock valued at $1,803,000 after purchasing an additional 34,034 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 969 shares during the last quarter. Finally, Palumbo Wealth Management LLC bought a new position in uniQure in the 4th quarter worth approximately $437,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 28,341 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $291,628.89. Following the completion of the sale, the chief executive officer now owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. This trade represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the transaction, the chief financial officer now owns 152,372 shares of the company’s stock, valued at $1,630,380.40. This trade represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,830 shares of company stock valued at $961,401 in the last 90 days. 4.74% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of uniQure in a report on Monday. Chardan Capital initiated coverage on shares of uniQure in a research report on Tuesday, April 1st. They issued a “buy” rating and a $38.00 price target on the stock. Wells Fargo & Company cut their price objective on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research report on Friday, February 28th. Finally, StockNews.com raised uniQure to a “sell” rating in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.80.

uniQure Stock Performance

QURE stock opened at $14.39 on Thursday. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business’s 50 day moving average is $11.92 and its 200-day moving average is $11.42. The firm has a market cap of $778.17 million, a P/E ratio of -2.90 and a beta of 0.42.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.